Monday, October 28, 2024 , at 8:30 a.m. EDT DUBLIN and CHICAGO , Oct.
28, 2024 /PRNewswire/ -- WHO: Iterum Therapeutics plc (Nasdaq: ITRM) is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. WHAT: Conference call to discuss U.S.
Food and Drug Administration (FDA) approval of Iterum's ORLYNVAHTM (Oral Sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs). Speakers include: Corey Fishman (CEO) and Steve Aronin (Senior Vice President and Head of Clinical Development WHY: ORLYNVAHTM (sulopenem etzadroxil and probenecid) is the first oral penem approved for use in the U.S.
and the first FDA-approved product for Iterum. ORLYNVAHTM is approved for the treatment of uUTIs caused by the designated microorganisms Escherichia coli , Klebsiella pneumoniae or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options. It is only the second FDA-approved treatment for uUTIs in the past two decades.
For more details, view the press release issued Friday here . WHEN: Monday, October 28, 2024 8:30 a.m.
Eastern Daylight Time Dial-in information: United States: +1 833-470-1428 | International: +1 404-975-4839 Access code: 936149 The conference call replay will be available in the Events & Presentations page of Iterum's website following the .
